ANCA-asszociált vasculitis: vizsgálatok itt: Kína
38 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2/3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Where
- Beijing, Hangzhou
- Életkor
- 18 év and over
- People
- 166
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT05979051 - No phaseTaking people(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Ruijin Hospital
See details and how to joinNCT07151521 - 1. fázisTaking peopleCAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129 - 1. fázisNot yet taking people in KínaThe Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
- Where
- Wuhan
- Életkor
- 18 év to 60 év
- People
- 12
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07033299 - Korai 1. fázisNot yet taking people in KínaClinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Peking University People's Hospital
See details and how to joinNCT06986018 - 1. fázisTaking peopleA Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 44
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06980597 - 1. fázisNot yet taking people in KínaUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
- Where
- Changzhou
- Életkor
- 18 év and over
- People
- 18
- Run by
- Changzhou No.2 People's Hospital
See details and how to joinNCT06978738 - 2. fázisTaking peopleBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT06794008 - Korai 1. fázisNot yet taking people in KínaThe Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
- Where
- Wenzhou
- Életkor
- 18 év to 65 év
- People
- 9
- Run by
- First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT06420154 - No phaseTaking peopleRefractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
- Where
- Wuhan
- Életkor
- 18 év to 70 év
- People
- 24
- Run by
- Lingli Dong
See details and how to joinNCT06277427 - 4. fázisTaking peopleEfficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 40
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT05965284 - 4. fázisTaking peopleEfficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 40
- Run by
- Chinese SLE Treatment And Research Group
See details and how to joinNCT05962840 - No phaseTaking peopleMulticenter Cohort Study of AAV in Hunan of China
- Where
- Changsha
- People
- 500
- Run by
- Xiangya Hospital of Central South University
See details and how to joinNCT05315141